this strategy is particularly relevant for asthma, cystic fibrosis, pulmonary fibrosis and lung cancer
The GLP-1 pathway reduces appetite by slowing gastric emptying, signaling fullness to the brain, and reducing food reward pathways
GLP-1 agonists are typically injectable medications, whereas SGLT2 inhibitors are available in pill form
Working With Your Prescriber: Patients experiencing persistent or troublesome symptoms should discuss treatment with their prescriber before increasing their dose
These medications include semaglutide (Wegovy) and tirzepatide (Zepbound), which are FDA-approved for chronic weight management, while semaglutide (Ozempic) and tirzepatide (Mounjaro) are approved for type 2 diabetes management
Kiwifruit (Actinidia deliciosa) changes intestinal microbial profile